Pharvaris N v
Officers & Directors
Berndt Modig is the Chief Executive Officer and Executive Director of Pharvaris, a company he co-founded and has led since its inception. His prior roles include Chief Financial Officer (CFO) of Prosensa Holding N.V. (2010–2015), CFO at Jerini AG (2003–2008), CFO at Surplex AG (2001–2003), Finance Director Europe at Hayward Industrial Products Inc. (1999–2001), Partner at Agra Industria (1994–1999), and Senior Manager at Price Waterhouse LLP (1991–1994).
Hans Schikan, Pharm.D., is a Non-Executive Director and co-founder of Pharvaris, serving on the board since 2019. He was CEO of Prosensa Holding N.V. from 2009 to 2015 and previously held Vice President positions at Genzyme. He is Chairman of the Board at Vicore Pharma and Microbiotica and serves as a board member of Organon N.V.
David Meeker, M.D., has been a Non-Executive Director at Pharvaris since 2021. He is Chairman of the Board, President, and CEO of Rhythm Pharmaceuticals, Inc. His previous roles include CEO of KSQ Therapeutics, Inc. (2017–2020), various executive positions at Sanofi Genzyme (2011–2017), and Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic. He has been Chair of Trevi Therapeutics since 2017 and a board member of Kardigan since 2024.
Pharvaris N v currently has 35 employees.
News about Pharvaris N v Key Personnel |
Pharvaris Charts a Course for Strategic Growth Amidst Financial ChallengesOverview of Pharvaris’ Strategic Vision for 2025ZUG, Switzerland – On January 13, 2025, Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company, unveiled its strategic priorities for the coming year. With a focus on addressing the unmet needs of patients suffering from bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema (AAE), Pharvaris aims to leverage its expertise in developing novel, oral bradykinin B2 receptor antagonists.Recent Financial PerformanceDespite its promising pipeline, Pharvaris has faced notable financial difficulties. For the 12 months ending in the fourth quarter o...
|
Pharvaris Appoints Seasoned Financial Expert as Chief Financial Officer
ZUG, Switzerland, April 10, 2024 - Pharvaris, a leading biopharmaceutical company specializing in the development of innovative oral bradykinin B2 receptor antagonists for the treatment and prevention of hereditary angioedema (HAE) attacks, has recently announced the appointment of David Nassif, J.D., as its new Chief Financial Officer. The appointment will be effective from April 15, 2024. Nassif will assume responsibility for refining and implementing Pharvaris corporate financial strategy and activities, which include financial reporting and operations. With over three decades of extensive experience in financial management, stra...
|
|
|
